Payment overview · 2025
General Payments
$327.96
15 reported records · 7 companies
Healthcare provider profile · identity verified
Arthur Equinozzi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PENN YAN, NY · NPI 1386733715
Verified facts
What the public records show
CMS Open Payments records show Arthur Equinozzi, M.D. received $327.96 in general payments during 2025 across 15 reported records.
PFIZER INC. accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexium by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.17 | 22.6% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.35 | 16.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $51.35 | 15.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.18 | 14.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.60 | 13.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $43.41 | 13.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.90 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $327.96 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $52.35 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $51.95 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $51.35 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $47.18 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.18 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.60 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.60 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $43.41 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 151 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 98 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
97 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
98 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
81 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
151 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1071 | 283 |
| Atorvastatin Calcium | Atorvastatin Calcium | 949 | 295 |
| Amlodipine Besylate | Amlodipine Besylate | 742 | 229 |
| Lisinopril | Lisinopril | 621 | 183 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 612 | 180 |
| Omeprazole | Omeprazole | 456 | 138 |
| Losartan Potassium | Losartan Potassium | 418 | 128 |
| Pantoprazole Sodium | Pantoprazole Sodium | 342 | 100 |
| Duloxetine Hcl | Duloxetine Hcl | 341 | 85 |
| Metformin Hcl | Metformin Hcl | 339 | 111 |
| Gabapentin | Gabapentin | 338 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 314 | 94 |
| Hydrochlorothiazide | Hydrochlorothiazide | 310 | 90 |
| Escitalopram Oxalate | Escitalopram Oxalate | 281 | 80 |
| Simvastatin | Simvastatin | 250 | 74 |
| Meloxicam | Meloxicam | 231 | 58 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 224 | 33 |
| Potassium Chloride | Potassium Chloride | 222 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 183 | 67 |
| Alendronate Sodium | Alendronate Sodium | 179 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 175 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 172 | 53 |
| Sertraline Hcl | Sertraline Hcl | 171 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 162 | 55 |
| Atenolol | Atenolol | 159 | 44 |
| Montelukast Sodium | Montelukast Sodium | 158 | 46 |
| Jardiance | Empagliflozin | 154 | 39 |
| Eliquis | Apixaban | 151 | 42 |
| Furosemide | Furosemide | 137 | 46 |
| Allopurinol | Allopurinol | 133 | 38 |
| Pregabalin | Pregabalin | 132 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 129 | 38 |
| Bupropion Xl | Bupropion Hcl | 128 | 29 |
| Trazodone Hcl | Trazodone Hcl | 124 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 26 |
| Carvedilol | Carvedilol | 105 | 26 |
| Fenofibrate | Fenofibrate Nanocrystallized | 103 | 24 |
| Lorazepam | Lorazepam | 100 | 23 |
| Ozempic | Semaglutide | 98 | 19 |
| Farxiga | Dapagliflozin Propanediol | 97 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 96 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 95 | 23 |
| Celecoxib | Celecoxib | 92 | 23 |
| Xarelto | Rivaroxaban | 91 | 19 |
| Metformin Hcl Er | Metformin Hcl | 89 | 22 |
| Baclofen | Baclofen | 88 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 88 | 64 |
| Famotidine | Famotidine | 88 | 27 |
| Ezetimibe | Ezetimibe | 87 | 21 |
| Synthroid | Levothyroxine Sodium | 87 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 84 | 25 |
| Tramadol Hcl | Tramadol Hcl | 84 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 25 |
| Rybelsus | Semaglutide | 81 | 27 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 78 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 20 |
| Warfarin Sodium | Warfarin Sodium | 78 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 71 | 13 |
| Trulicity | Dulaglutide | 71 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 70 | 20 |
| Prednisone | Prednisone | 70 | 26 |
| Telmisartan | Telmisartan | 70 | 23 |
| Chlorthalidone | Chlorthalidone | 66 | 17 |
| Irbesartan | Irbesartan | 66 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 64 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 62 | 14 |
| Lansoprazole | Lansoprazole | 62 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 15 |
| Azelastine Hcl | Azelastine Hcl | 60 | 25 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 59 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 14 |
| Felodipine Er | Felodipine | 58 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 58 | 12 |
| Alprazolam | Alprazolam | 57 | 22 |
| Ibuprofen | Ibuprofen | 56 | 14 |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Clonazepam | Clonazepam | 49 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 13 |
| Buspirone Hcl | Buspirone Hcl | 47 | 12 |
| Spironolactone | Spironolactone | 46 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 45 | suppressed |
| Mirtazapine | Mirtazapine | 45 | 13 |
| Amoxicillin | Amoxicillin | 39 | 22 |
| Valacyclovir | Valacyclovir Hcl | 39 | 15 |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 14 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 36 | suppressed |
| Cefdinir | Cefdinir | 35 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 14 |
| Glimepiride | Glimepiride | 35 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Topiramate | Topiramate | 32 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Colchicine | Colchicine | 30 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 14 |
| Methylphenidate Hcl | Methylphenidate Hcl | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 13 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Torsemide | Torsemide | 26 | 13 |
| Lovastatin | Lovastatin | 25 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 24 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Invokana | Canagliflozin | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Scopolamine | Scopolamine | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Epinephrine | Epinephrine | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 15 |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Sumatriptan | Sumatriptan | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Vivitrol | Naltrexone Microspheres | 15 | suppressed |
| Konvomep | Omeprazole/Sodium Bicarbonate | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 13 |
| Testosterone | Testosterone | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Brixadi | Buprenorphine | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Klor-Con M10 | Potassium Chloride | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 12 | 11 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $327.96 · 15 records | PFIZER INC. | ABRYSVO, AIRSUPRA, CAPLYTA, COMIRNATY, ELIQUIS, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, SHINGRIX, VOQUEZNA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error